Featured news in The Life Sciences Report



DURECT Corp. (DRRX:NASDAQ)
Significant Progress in Non-Opioid Therapy Picks up Steam As Market Projected to Reach $22 Billion by 2022 (3/16/2018)

view
 


Celgene Corp. (CELG:NASDAQ)
Why Multiple Sclerosis is a Promising but Risky Space? (3/16/2018)

view
 


MiMedx Group Inc. (MDXG:NASDAQ)
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. And Reminds Investors With Losses To Contact The Firm (3/16/2018)

view
 

MiMedx Group Inc. (MDXG:NASDAQ)
MIMEDX GROUP LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In MiMedx Group, Inc. To Contact The Firm (3/16/2018)

view
 


Viveve Medical Inc. (VIVE:NASDAQ)
Viveve Reports Fourth Quarter and Full Year 2017 Financial Results (3/15/2018)

view
 


MiMedx Group Inc. (MDXG:NASDAQ)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MiMedx Group, Inc. (MDXG) & Lead Plaintiff Deadline: April 25, 2018 (3/16/2018)

view
 


Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX)
New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies - Factors of Influence, Major Initiatives and Sustained Production (3/16/2018)

view
 


BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum (3/15/2018)

view
 


Cesca Therapeutics Inc. (KOOL:NASDAQ)
Cesca Therapeutics to Announce Financial Results for the Transition Period From July 1, 2017 to December 31, 2017 on March 22 (3/15/2018)

view
 


Caladrius Biosciences Inc. (CLBS:NASDAQ)
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time (3/15/2018)

view
 


MiMedx Group Inc. (MDXG:NASDAQ)
MiMedx Announces Expectation to Exceed the $92 Million Top End of First Quarter Revenue Guidance (3/15/2018)

view